Press Cutting

Client: Chi-Med

Publication: M2 Pharma

Date: 13 July 2009

Hutchison MediPharma's drug for treatment of CD shows positive results in Phase II trial

13 Jul 2009 - Chinese Hutchison MediPharma Ltd announced today positive results from the Phase II trial of HMPL-004, an oral drug for treatment of patients with active mild to moderate Crohn's Disease (CD).

The Phase II CD trial was a multi-centre, double blind, randomised, and placebo-controlled study conducted in 101 CD patients in the USA (73 patients) and Ukraine (28 patients). The clinical study included eight-weeks treatment with HMPL-004 or placebo and then 4 weeks of follow up.

The primary endpoint of the trial was to assess the efficacy, which is the percentage of subjects with a clinical response minus 100, defined as a reduction in Crohn's Disease Activity Index (CDAI) by at least 100 points from the baseline.

Secondary endpoints including the clinical response minus 70, defined as CDAI reduction of at least 70 points, and the percentage of subjects attaining remission, defined as CDAI score of 150 or less, were also assessed.

For the Intent-To-Treat (ITT) patient population, the clinical response -100 at week eight was 37% for HMPL-004 versus 22% for the placebo. The clinical response -70 at week eight was 49% for HMPL-004 versus 32% for the placebo. The remission rate at week 8 was 29% for HMPL-004 versus 14% for the placebo.

Currently, HMPL-004 is in Phase IIb trial for Ulcerative Colitis (UC) which involves 210 patients with mild-to-moderate UC conditions. The UC trial is near its patient recruitment target and is expected to complete and report results before the end of 2009.

Hutchison MediPharma is a wholly-owned drug research and development (R&D) subsidiary of **Hutchison China MediTech** Ltd (Chi-Med) (LON: HCM), which in its turn is majority owned by Hong-Kong-based port operator Hutchison Whampoa Ltd (HKG: 0013).

Comments on this story may be sent to info@m2.com